Working Paper Cnr-Ceris, N° 01/2014
Path-breaking directions
of nanotechnology-based chemotherapy
and molecular cancer therapy
Mario Coccia* National Research Council of Italy
Institute for Economic
Research on Firm and Growth
CNR-CERIS Collegio Carlo Alberto - via Real Collegio, n. 30 Tel.: +39 011 68 24 925; fax : +39 011 68 24 966; email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
Lili Wang
UNU-MERIT- Keizer Karelplein, n. 19 Tel.:+ 31 (0) 43-3884456
email: This email address is being protected from spambots. You need JavaScript enabled to view it.
|
Corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract: A fundamental question is how to detect likely successful anticancer treatments based on nanotechnology. We confront this question here by analyzing the trajectories of nanotechnologies applied to path-breaking cancer treatments, which endeavour to pinpoint ground-breaking and fruitful directions in nanomedicine. Results tend to show two main technological waves of cancer treatments by nanotechnology applications. The early technological wave in the early 2000s was embodied in some types of chemotherapy agents with a broad spectrum, while after 2006, the second technological wave appeared with new nano-technological applications in both chemotherapy agents and molecular target therapy. The present study shows new directions of nanotechnology-based chemotherapy and -molecular cancer therapy in new treatments for breast, lung, brain and colon cancers. A main finding of this study is the recognition that, since the late 2000s, the sharp increase of several technological trajectories of nanotechnologies and anticancer drugs seems to be driven by high rates of mortality of some types of cancers (e.g. pancreatic and brain ones) in order to find more effectiveness anticancer therapies that increase the survival of patients. The study here also shows that worldwide leader countries in these vital research fields and in particular the specialization of some countries in applications of nanotechnology to treat specific cancer (e.g. Switzerland in prostate cancer, Japan in colon, China in ovarian and Greece in pancreatic cancer). These ground-breaking technological trajectories are paving new directions in biomedicine and generating a revolution in clinical practice that may lead to more effective anticancer treatments in a not-too-distant future.
Keywords: Nanotechnology, Nanoscience, Biomedicine, Nanomedicine, Target Therapy, Chemotherapy, Cancer, Bibliometrics, Publications, Technological Trajectories.
JEL Codes: C89; O30, C53, I10
Acknowledgments: This research started by the authors in 2012 and it has been developed in 2013 while Mario Coccia was visiting scholar at the UNU-MERIT in Maastricht. We thank Prof. Bart Verspagen for fruitful suggestions to this paper. Mario Coccia gratefully acknowledges the CNR - National Research Council of Italy for financial support to this research project by the short mobility program at UNU-MERIT. Preliminary results have been presented at S.NET 4th Annual Meeting -Fourth annual conference of the society for the study of nano science and emerging technologies (October 22-25, 2012), University of Twente (The Netherlands). The usual disclaimer applies.